# Uncovering Novel Mechanisms Driving Opioid-Induced Hyperalgesia

Adhwita Nair

## Introduction

The opioid epidemic is a significant public health crisis characterized by widespread misuse and addiction to prescription medication and/or narcotics. The surge in deaths due to overdosing correlates directly with the rise of synthetic opioids, which are laboratory-created substances that are far more potent than natural opioids. Opioid consumption can also lead to the development of opioid-induced hyperalgesia (OIH), a devastating and understudied condition. OIH is defined as a state of nociceptive sensitization caused by opioid exposure, observed historically in patients receiving morphine for pain relief. This response highlights a key issue in chronic opioid therapy, where analgesic treatment can inadvertently lead to heightened pain sensitivity. This condition occurs when prolonged opioid use paradoxically increases sensitivity to pain, leading to heightened discomfort and reduced pain relief over time[1]. OIH complicates pain management efforts, as patients may require escalating doses of opioids to achieve the same level of relief, thereby increasing the risk of dependency and overdose. Recognizing OIH as a potential consequence of opioid therapy underscores the urgent need for healthcare providers to explore alternative pain management strategies and prioritize patient safety in combating the broader opioid epidemic.

Patients suffering OIH have recorded pain perception being increased to such an extent that even the feeling of clothing on the body is a painful sensation. The interplay of various systems and mechanisms in the brain that all contribute to OIH is complex but has yet to be extensively reviewed. The main mechanisms hypothesized to contribute significantly to this syndrome include the dorsal root ganglion (DRG), glial cells, and neuropeptides.

The DRG is a structure of clusters of neurons found in the dorsal horn of the spinal cord. As a hub for sensory input from the body, the DRG has a strong role in nociception. It contains various cell types that aid in the perception and processing of sensory signals. Some of these cell types include specialized DRG neurons that transmit pain signals to the central nervous system (CNS), and glial cells, which are especially relevant to this paper.  Glial cells have many subtypes, including microglia, Schwann cells, oligodendrocytes, and satellite cells. While all carry slightly varying functions, all these cell types are known to travel throughout the brain and spinal cord to respond to inflammation, injury, or foreign substances. Should they encounter a bodily threat, glial cells will undergo glial cell activation to fight the insult. Glial cells additionally regulate several physiological processes, such as the concentration of ions, small proteins, and solutes in the brain. These concentrations can also be dysregulated while undergoing glial cell activation. This is where small proteins called neuropeptides are involved. Neuropeptides can

act as neurotransmitters or neuromodulators, playing diverse roles in neuronal communication, including neuronal excitatory modulation and pain perception. The activation of glial cells in the DRG, and their impact on neuropeptides contributes to OIH in a manner that has yet to be explored in current literature.

**Results**

Endogenous versus exogenous opioids

Opioids can be classified as either endogenous (originating from within the body) or exogenous (opioids that have been taken into the body). Morphine, heroin, and fentanyl are classified as exogenous opioids. Endogenous opioids include endorphins or enkephalins and carry functions covering metabolism, cardiovascular regulation, and most notably, pain perception. Endogenous opioids bind to endogenous opioid receptors in the brain, such as the μ receptor, to carry out some of these functions. During consumption of opioids, the exogenous opioids will enter the bloodstream, pass the blood-brain barrier, and soon take the place of endogenous opioids by binding to endogenous opioid receptors[2]. There, exogenous opioids cause an inhibitory effect on the surrounding neurons: it stops the release of the neurotransmitter glutamate from endogenous opioid receptors, halting communication between endogenous opioid receptors, and all the aforementioned functions of the receptors are now not being carried out by the brain. So, when it comes to certain functions like nociceptive perception, the brain will stop perceiving pain. While the phenomenon aids in the feeling of a “high” while under opioid consumption, after that “high” is over, endogenous opioid receptors will have grown accustomed to being barely stimulated. After exogenous opioids leave the body, those receptors get an overload of stimulation, in contrast to the near zero stimulation before, which altogether causes a distorted and increased perception of pain[3].




**Figure 1. Model of receptor stimulations before and after opioid consumption.**
Endogenous opioid (blue). Exogenous opioid (orange). Endogenous Opioid Receptor (purple). Created with BioRender.com

The hidden mechanisms behind opioid-induced hyperalgesia:
Opioid use undoubtedly has negative effects on the human body, ranging from physical to psychological changes. While under the influence of opioids, the brain experiences a new kind of stress. Inflammation is the body's primary response to dealing with injury, foreign substance, and infection. The stress following opioid use that the brain undergoes can be categorized in these ways and often results in inflammation in the brain. This inflammation has a direct connection to OIH via glial cell activation. Glial cells, specifically microglia and astrocytes, in both the CNS and peripheral nervous system interact closely with neurons to modulate pain. In the DRG, glial cells become activated in response to signals from nociceptors that are injured or inflamed due to opioid use. These glial cells release pro-inflammatory cytokines and chemokines that further sensitize the nociceptors, leading to increased pain perception. Glial cell activation enhances peripheral sensitization (increased sensitivity to stimuli at the injury site) and central sensitization (amplification of pain signals in the CNS). This process involves the dysregulation of nociceptive neuropeptides, which are crucial for transmitting pain signals[4].

While under stress from fighting to respond to inflammation, glial cells undergo activation. Neuropeptides that are released from sensitized nociceptors not only induce local inflammation but also are influenced by glial cell activation, creating a feedback loop that exacerbates pain. In the DRG, neuropeptides can modulate the function of satellite glial cells, leading to the release of additional inflammatory mediators and maintaining a state of heightened pain sensitivity. This interaction extends to the CNS, where neuropeptides and glial-derived factors facilitate central sensitization—a process where pain signals are amplified and prolonged.

**Discussion**

This study went over the intersection between OIH and the dysregulation of neuropeptides in dorsal root ganglia due to glial cell activation. Understanding how OIH involves glial cell activation and its impact on nociceptive neuropeptides is a significant breakthrough in pain research. It goes beyond just opioid receptors and shows that OIH is influenced by complex interactions in the nervous and immune systems. OIH has to date been researched with findings only relating to endogenous opioid receptors being the area of issue. However, this paper challenges that notion with the introduction of the possibility of different systems at play, those systems being glial cell activation and neuropeptides. This understanding not only improves theoretical models of pain but also suggests new ways to treat it. For instance, by targeting glial cells, there might be better ways to manage hyperalgesia or even further research in pain perception.

The primary aim was to explain the role of glial cell activation in OIH and its effect on nociceptive neuropeptides. The reviewed literature supports the hypothesis that glial cells indeed play a crucial role in the dysregulation of pain sensitivity associated with OIH. Further, OIH involves mechanisms beyond opioid receptor desensitization, which showcases new pain pathways and different brain mechanisms at work.

Acknowledging the study's limitations is crucial for a balanced view. One significant aspect is the reliance on observational data from research papers and data from other review papers, which may not fully replicate real-world scenarios in individuals undergoing long-term opioid therapy. This could limit the generalizability of the findings to human populations. Additionally, variations in how glial cells respond to different opioids and among diverse patient groups introduce differences and complexities that might need to be studied further. In conclusion, this review uncovers the intricate roles of glial cells in regulating nociceptive neuropeptides, which advances the opioid field's understanding of traditional pain pathways and management.

**Methods**

While conducting this literature review, the primary search strategy was the utilization of the literature database, PubMed, which offers access to a wide array of peer-reviewed journals in the biomedical and life sciences fields. The search strategy involved the use of certain keywords

related to the research question to find articles which were then sorted by relevance. The search terms used included “DRG”, “Glial Cell”, “Glial Cell Activation”, “Opioid-Induced Hyperalgesia”, “Neuropeptides”, and “Neuropeptide Y”. Eligible articles included one or more of these keywords and were conducted in the last 10 years, to avoid using outdated information. This review paper covers the intersection of various areas and mechanisms of the brain, so the criteria for each paper reviewed was mainly that it should cover one of those areas in depth. Study designs of papers used were mainly review papers or studies done on humans. Studies done on animals or surveys were among the study designs avoided in finding literature for this paper. The synthesis method was mostly narrative synthesis, synthesizing information that related to the mentioned topics and supported the hypothesis with proper evidence.

**Acknowledgments**
The author would like to thank Merci N. Best, Rajasree Nair, and Rajesh Nair for their support and encouragement.

**References**
1. Mercadante, S., Arcuri, E. & Santoni, A. Opioid-Induced Tolerance and Hyperalgesia. CNS Drugs **33**, 943–955 (2019).
2. Holden, J. E., Jeong, Y. & Forrest, J. M. The endogenous opioid system and clinical pain management. AACN Clin Issues **16**, 291–301 (2005).
3. Lee, M. O. et al. A Comprehensive Review of Opioid-Induced Hyperalgesia. Pain Physician **14**, 145–161 (2011).
4. Donnelly, C. R. et al. Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain. Neurotherapeutics **17**, 846–860 (2020).